Genentech, Inc.

Merck Sharp + Dohme Corp.

Schering Corporation

Compugen Ltd. Corporation

Igm Biosciences, Inc.

Pierre Fabre Medicament

Genetech, Inc.

The Scripps Research Institute

Zymeworks Inc.

Gilead Sciences, Inc.

Intervet Inc.

Other

Xencor, Inc.

Alexion Pharmaceuticals, Inc.

Seattle Genetics, Inc.

Leonard G Presta

Paul J Carter

Paula M Jardieu

Roman Urfer

Henry Bernard Lowman

Christopher Chan

Napoleone Ferrara

Bruce Alan Keyt

Mark Leslie White

Gad S Cojocaru

Shirley Sameah-Greenwald

John William Winslow

Liat Dassa

Spencer Liang

Zohar Tiran

Sandeep Kumar

Ilan Vaknin

Lance Stapleton

Andrew W Drake

Yosi Gozlan

Richard Theolis

Camellia W Adams

Helen Hsifei Chen

Terri Lynn Davis-Smyth

David L Shelton

Ramesh Baliga

Steven R Leong

John B Lowe

John B Ridgway

Michael George Mulkerrin

Venkataraman Sriram

Esohe Ekinaduese Idusogie

Bradley Richard Snedecor

Fen Zhang

Mohan Srinivasan

James A Wells

Timothy Andrew Stewart

Mark X Sliwkowski

Manuel Baca

Peter Brams

Denise Leah Williams

Jonathan A Pachter

Edward Thein Htun Van Der Horst

Yvonne Man-Yee Chen

John Lippincott

Yan Wang

Stephen P Anderson

Rene De Waal Malefyt

Zahra Shahrokh

Anan Chuntharapai

Linda Liang

Kyle Hansen

Bruce A Keyt

Iphigenia Koumenis

Vanessa Hsei

Radhika Chetan Desai

Maya Kotturi

Peter G Schultz

Travis Young

Peter Orth

Gerardo A Zapata

Edward P Bowman

Brian M Beyer

Michel Streuli

Richard N Ingram

Xiao Min Schebye

Ellen Filvaroff

Nils Lonberg

Mark Zoller

Mohamad A Morsey

Brigitte Devaux

Jo-Anne Hongo

Daniel Kirchhofer

Joseph H Phillips

Ian Tarpey

Gerald R Nakamura

Yuanzheng Zhang

Eric Escobar-Cabrera

Kathy Miller

Andrew C Chan

David G Lowe

Sayantan Mitra

Denise Bartels-Morozov

Jason Erskine

Naoya Tsurushita

Jagath Reddy Junutula

Svetlana Doronina

Stephen Fitzhugh Carroll

Laurence A Lasky

Genmin Lu

Chuan-Chu Chou

Thomas Spreter Von Kreudenstein

Pamela B Conley

Mario Sanches

Robert L Shields

Gordon Yiu Kon Ng

Dunja Urosev

Tony Liang

Stacey A L Tom-Yew

Ying-Ping Jiang

Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.

Anti-TREM2 antibodies and related methods

Antibody-drug conjugates (ADCs) are described, comprising anti-TM4SF1 antibodies, and antigen-binding fragments thereof. Methods of use of said ADCs are also described.

Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same

Provided herein are anti-MARCO antibodies. Provided are also methods of generating and using anti-MARCO antibodies.

Anti-MARCO antibodies and uses thereof

This invention provides for a fusion protein between a single chain TNFR2 Selective Agonist protein (scTNFR2 Selective Agonist) and a dimerization domain, such as an IgGFc protein. The single chain TNFR2 Selective Agonist moiety provides a therapeutic activity by selectively activating the TNFR2 form of the TNF-α receptor, thus selectively stimulating Tregs and/or increasing myelin deposition.

Single-chain TNF Receptor 2 agonist fusion proteins

Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.

Nucleic acids encoding, and methods of producing, antibodies that bind human chemokine (C—C motif) receptor 8 (CCR8)

The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.

Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof

Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2. The antigen-binding constructs comprise at least one antigen-binding polypeptide construct that binds to ECD2 of HER2 (HER2 ECD2) with increased affinity compared to a wild-type 2C4 antibody. Such antigen-binding polypeptide constructs comprise one or more amino acid modifications in the framework region and/or CDRs compared to the amino acid sequence of a wild-type 2C4 antibody that increase affinity of the antigen-binding polypeptide construct for ECD2 by 2-fold or greater. The antigen-binding constructs can inhibit the growth of HER2-expressing breast cancer cells and gastric cancer cells. Antigen-binding constructs in biparatopic format are internalized in HER2-expressing cells.

Antigen-binding constructs targeting HER2

The present disclosure relates to antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. In one embodiment, the derivatives described herein lack or have reduced intrinsic coagulant activity.

Antidotes to factor XA inhibitors

Provided herein are common light chain bispecific antibodies that bind CD38 and CD19. The common light chain bispecific antibodies comprise an anti-CD38 heavy chain variable region and anti CD19 heavy chain variable region that each have a negatively-charged amino acid at a terminal heavy chain variable region position. The common light chain bispecific antibodies comprise further comprise an anti-CD38 heavy chain constant region and anti-CD19 heavy chain constant region that each lack a C-terminal lysine residue. Further provided are nucleic acids encoding such common light chain bispecific antibodies and host cells comprising the nucleic acids. Also provided are methods of making such common light chain bispecific antibodies.

CD19/CD38 multispecific antibodies

Provided herein are anti-TREM1 antibodies and related methods of making and using anti-TREM1 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM1 antibody or antigen binding fragment thereof.

Anti-TREM1 antibodies and related methods

The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.

Anti-C10orf54 antibodies and uses thereof

The present invention is directed to anti-PVRIG antibodies and methods of using same.

Anti-PVRIG antibodies and methods of use

Anti-PVRIG and anti-TIGIT antibodies are provided.

Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof

Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)

The present invention provides binding molecules that include an IgM, IgA, IgG/IgM or IgG/IgA antibody with a modified J-chain that includes a binding moiety that antagonizes a T-cell inhibitory signaling pathway, and their uses.

Binding molecules with modified J-chain

Growing community of inventors

San Francisco, CA, United States of America

Leonard G Presta